Shenzhen YHLO Biotech (SHA:688575) obtained medical device registration from Guangdong's drug regulator for its fully automated fluorescence immunoassay analyzer.
The system supports multiplex liquid-phase detection and can process up to 72 samples per hour, with applications initially focused on autoimmune antibody testing, according to a Thursday filing with the Shanghai bourse.
The registration is valid until November 2030.
Shares of the biotechnology company closed 1% higher Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments